Revive Therapeutics Ltd. RVV
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.81% | -1.65% | -45.50% | 105.15% | -67.34% |
| Depreciation & Amortization | -- | -- | -- | -100.00% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.83% | -1.65% | -59.99% | 42.16% | -75.64% |
| Operating Income | -0.83% | 1.65% | 59.99% | -42.16% | 75.64% |
| Income Before Tax | 8.20% | 34.28% | 40.94% | -267.12% | 71.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.20% | 34.28% | 40.94% | -267.12% | 71.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.20% | 34.28% | 40.94% | -267.12% | 71.03% |
| EBIT | -0.83% | 1.65% | 59.99% | -42.16% | 75.64% |
| EBITDA | -0.81% | 1.65% | 59.99% | -42.25% | 75.64% |
| EPS Basic | 20.00% | 33.33% | 37.50% | -264.44% | 72.22% |
| Normalized Basic EPS | 16.67% | 60.00% | 40.00% | 33.33% | 72.73% |
| EPS Diluted | 20.00% | 33.33% | 37.50% | -264.44% | 72.22% |
| Normalized Diluted EPS | 16.67% | 60.00% | 40.00% | 33.33% | 72.73% |
| Average Basic Shares Outstanding | 4.09% | 4.09% | 2.57% | 1.16% | 7.77% |
| Average Diluted Shares Outstanding | 4.09% | 4.09% | 2.57% | 1.16% | 7.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |